Anne F. Luetkemeyer, MD

Phone: 415-476-4082 ext. 130
UCSF Box: 0874
Email: aluetkemeyer@php.ucsf.edu
UCSF Profile

Project Sponsor
Location(s) Topics Start End
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of a Novel CCR5 Antagonist, UK427,857, for the Treatment of Antiretroviral-Experienced HIV-1-Infected Subjects Pfizer United States HIV/AIDS, Pharmacology and Drug Treatment
ViiV Healthcare A4001098 Pfizer United States
Pfizer A4001027: Observational Phase Extension Pfizer United States HIV/AIDS, Pharmacology and Drug Treatment
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia Bristol-Myers Squibb Company United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C Bristol-Myers Squibb Company France; Germany; Hungary; Spain; Argentina Sexually Transmitted Infections (STIs)
Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination with Ribavirin and Daclatasvir for Treatment of Chronic HCV Infection with Treatment Naïve Genotypes 1, 2, 3 or 4 in Subjects Coinfected with HIV-1 Bristol-Myers Squibb Company United States HIV/AIDS
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV Bristol-Myers Squibb Company France; Germany; Italy; Russia; Spain; United Kingdom; Argentina; Puerto Rico; Canada; Australia HIV/AIDS
Gilead GS-US-236-0102 Gilead Sciences, Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
GS-US-183-0130: A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects Gilead Sciences, Inc. United States HIV/AIDS
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti Gilead Sciences, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection Gilead Sciences, Inc. United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) Coinfected Subjects (GS-US-334-0123) Gilead Sciences, Inc. United States Sexually Transmitted Infections (STIs)
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy (ACTG) A5260s Social & Scientific Systems, Inc. United States HIV/AIDS
Metabolic Substudy of A5257, CIMT/FMD Repeat Scans (ACTG A5260s:) Social & Scientific Systems, Inc. United States HIV/AIDS
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects Cepheid United States HIV/AIDS, Tuberculosis
Cepheid 077B-C: Evaluation of the Xpert® MTB/RIF Assay Cepheid Uganda; United States Tuberculosis
A phase III trial to investigate the efficacy, tolerability & safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects w/ limited to no treatment options Tibotec Pharmaceuticals Ltd United States HIV/AIDS, Pharmacology and Drug Treatment
Tibotec TMC125-C214: Early Access of TMC125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment 0ptions Tibotec Pharmaceuticals Ltd United States HIV/AIDS, Pharmacology and Drug Treatment
A Probe to Evaluate the Safety, Tolerability & Immunogenicity of the MRK Adenovirus Serotype 5 Vector Human Immunodeficiency Virus Type 1 gag Vaccine in HIV-1 Infected Merck and Co., Inc. United States HIV/AIDS
DAIDS A5298 Study: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men Merck and Co., Inc. Brazil; Puerto Rico HIV/AIDS, Cancer/Oncology
ACTG A5294: A Prospective, Phase III Open-Label Study of Response-Guided Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects Merck and Co., Inc. United States HIV/AIDS
Tobira 652-2-202 Pre-Clinical Trial Cost Agreement Tobira Therapeutics United States HIV/AIDS, Pharmacology and Drug Treatment
ACTG, AIDS Clinical Trials Research Group - A5289 and A5255 Brigham and Women's Hospital United States HIV/AIDS
Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 and ABT-333 Coadministered with Ribavirin in Adults with Genotype 1 Chronic HCV and HIV AbbVie Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy Merck Sharp & Dohme Corp United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment